4basebio UK Societas is developing next-generation gene therapy technologies and solutions.
4basebio started with a focus on the manufacture of synthetic DNA for use in gene therapies; our synthetic DNA has clear safety, efficacy, and cost benefits over current plasmid DNA. Our near-term objective is the development of Good Manufacturing Practice (GMP) grade synthetic DNA as a key milestone in the commercialisation of this core technology.